HNC042
/ Henovcom
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 23, 2023
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
May 24, 2021
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Trial completion date: Oct 2020 ➔ Oct 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021
Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases
October 27, 2020
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Clinical • New P1 trial • Infectious Disease
1 to 3
Of
3
Go to page
1